Targeting a specific protein to treat muscle and bone loss in cancer patients
Targeting RANKL for the treatment of muscle and bone defects in cachexia
This study is looking at how a protein called RANKL affects bone and muscle loss in cancer patients, especially those with ovarian cancer, to help find better ways to treat these tough symptoms.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project ID | NIH-10993158 on NIH RePORTER |
What this research studies
This research investigates the role of RANKL, a protein involved in bone resorption, in the context of cachexia, a condition characterized by severe muscle and weight loss in cancer patients. The study aims to understand how RANKL contributes to bone and muscle deterioration in individuals with advanced cancer, particularly focusing on those with ovarian cancer. By exploring the mechanisms behind this process, the researchers hope to develop new treatment strategies that could mitigate these debilitating symptoms. The approach includes both animal models and patient observations to gather comprehensive data on the effects of RANKL on muscle and bone health.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with advanced cancer, particularly those experiencing cachexia and related musculoskeletal complications.
Not a fit: Patients who do not have cancer or those without symptoms of cachexia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that improve muscle and bone health in cancer patients suffering from cachexia.
How similar studies have performed: Previous studies have shown promising results in targeting RANKL for bone health, suggesting that this approach may be effective in treating cachexia-related complications.
Where this research is happening
Aurora, UNITED STATES
- University of Colorado Denver — Aurora, United States (Active)
Researchers
- Principal investigator: Bonetto, Andrea — University of Colorado Denver
- Study coordinator: Bonetto, Andrea
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.